Updated Oct 02, 2018

To Enable Proper Dosing for Effective Treatment of Hemolytic Disease of the Fetus and Newborn (HDFN) in Africa

Part of University of Toronto

The innovation has no owner

CLAIM IT

Snapshot

Focus Areas:

Maternal Newborn and Child Health

Maternal Newborn and Child HealthSEE LESS

Implemented In:

Egypt

EgyptSEE LESS

1
Country Implemented In
Verified Funding
?

Innovation Description

In Rhesus D hemolytic disease of the newborn, fetal red blood cells are destroyed by the maternal immune system through the placenta, causing devastating consequences for fetus (e.g., severe anemia, neurologic injury, stillbirth, and neonatal death) [1-2]. In African hospitals, the dose of the drug (an expensive and a potentially scarce blood product) given to patients is ad hoc, preventing effective treatment, exacerbating affordability, and hindering broad access of the drug in Africa [3-5].

Milestones

Mar 2018
Funds RaisedVERIFIED
$75,000
Date Unknown
New Country
Egypt
Date Unknown
New Country
Egypt